The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Taken from an interview with the CEO of ghh published on Dec 2022 :-
'According to the latest results presentation, industrial applications now account for just over half of the firm’s sales, with the remainder split evenly between life sciences, and aerospace and defense.
Looking ahead, Peppiatt says that “demand fundamentals” remain strong across all three of those key market sectors, with new program wins in defense applications, and demand for specialist industrial lasers rebounding in support of 5G infrastructure roll-out and advanced semiconductor production.
“We can see that the conflict in Ukraine has reinforced the continuing importance of armored systems in modern warfare,” noted the CEO in his statement, with orders for programs intended to replenish equipment that has been provided to the country following Russia’s invasion.
Key wins are said to include a “significant position” on the UK MoD’s program to update the optical sensor suite for its Challenger tank program, while solid demand for gimballed optical arrays produced in New Hampshire are anticipated in both Europe and Asia.
Escalating geopolitical tensions have also prompted some huge investments to re-establish high-volume chip manufacturing in Europe and the US, something that could benefit G&H in the medium term.
Outlining what he sees as the promising areas for business growth, Peppiatt highlighted opportunities in components and modules needed for extreme ultraviolet (EUV) lithography equipment in semiconductor wafer processing, fiber-optic modules and subsystems for lidar sensing and optical satellite communications, and biomedical imaging systems for diagnosing cancer and cardiovascular disease.
Other key areas are thought to include photonics systems for ophthalmology equipment, optical components for gimbals in military drones, and multi-band periscopes and sighting systems for armored vehicles.'
Several of Zeus's top 10 ideas for 2023 are recovery plays, which is hardly surprising given the sell-offs experienced last year. Shares in Gooch & Housego (GHH) more than halved after the optical technology specialist struggled to find enough staff and components to meet demand. However, the orders kept flowing and restructuring processes have made savings. The strategic review currently being undertaken by new CEO Charlie Peppiatt (formerly of Stadium and TT Electronics) "should add impetus to the recovery and growth strategy", the broker argued. The sell-off also mean GHH shares are trading at a discount to their long-run average.
G&H is pleased to announce that we will be attending the SPIE BiOS and Photonics West exhibitions, taking place January 28 to January 29, 2023 and January 31 to February 2, 2023 in San Francisco, CA. These premier events bring together leading companies, researchers, and experts in the photonics industry to highlight the latest advancements in technology and applications.As a leading provider of innovative photonics solutions, G&H is excited to participate in these important events and share our latest products with attendees. Our team will be on hand to discuss our cutting-edge solutions and answer any questions attendees may have.
"BiOs and Photonics West are always highlights of the year for our company," said Stratos Kehayas, CCO of G&H. "We are thrilled to have the opportunity to connect with industry leaders, learn about the latest developments in the field, and showcase our own innovations to the photonics community. This year visitors will have the opportunity for a sneak preview of our two brand new Fiber-Q products: The iFiber-Q and the Fiber-Q ULTRA that offer low SWaP and ground-breaking performance. We will also be presenting progress on extremely powerful optical sources for Terabit capacity satellite links as part of the technical conference on free space optics."
G&H will be showcasing our full range of products, including our high-performance laser systems, advanced optical components, and custom photonics solutions. Attendees will also have the opportunity to learn about our cutting-edge research and development efforts and explore potential partnerships and collaborations.
This aim share is only beginning to recover from its 2022 low and is worth looking at for it's triple armed business strategy plus it's ex divi on Thursday.
And the director buys keep coming
Defence and aerospace spending is taking off. BAE Systems to recruit 2600 apprentices and graduates in 2023 in increasing opportunities in this field. Also bound to be reflected within GHH's aerospace and defence business arm going forward.
Peel Hunt cuts ghh target price from £10 to £7.50 on 13th December.
I take a contrary view myself based on the record order book the future defence spending boon not to mention that vastly oversold sp.
Still £7.50 is 50% higher than today's high of £5.
Yes, it is an AIM stock and probably getting excited about nothing. Thinks it`s just the shock of seeing this move up as been holding for Months now and only seeing it go down. Need to calm down and let it find its true level. Good luck on a 300% profit. Cant remember the last time i had one like that if at all. Always bail out too quickly if I have been losing on a share.
Duh, it's an Aim stock with a small market cap so these sorts of move's are normal for ghh, just take a look at past charts and all will become clear. I'm riding this one back to its previous highs and beyond and in no hurry obviously, take a 10% profit if you wish I prefer a 300% profit myself.
May well be just supply and demand. The market forced it down on results day, flushed a few out, but in reality more buys than sells at this price, hence a rapid rise. Note it was Algo trades, that hoovered up the stock. However the bid was still at 450p so dont get too excited.
That may well be the case but thats quite a few Months away. This is the biggest rise in one day I have seen since I initially bought in around £6.40 and seen it fall ever since. Not complaining though as nearly at break even after other buys, but why has it gone up over 10% Today late on. I do suspect there is news to come on Monday to explain this. Either a big order or bid offer will suit Me. Probably wont amount to anything though and was tempted to sell a few but held back. Hope I`ve made right decision this time.
Analysts expect a massive rise in earnings per share in the next year. If the dividend continues along recent trends, we estimate the payout ratio will be 53%, so there isn't too much pressure on the dividend.
RNS on Monday with bid offer. I wish. News must be coming though from insiders to buy into a falling share.
At last!
finnCap forecasts a partial recovery in profit tax profit to £9.3m in 2022-23, rising to £11.8m in 2023-24. The shares are trading on less than 15 times prospective 2022-23 earnings, falling to 12 the following year.
From UK Share Magazine 9hrs ago:-
Gooch & Housego has previously had a higher rating because of its technology expertise and potential for growth. There is substantial recovery potential at this share price.
RNS - Second PMDR purchase today. CEO @ 5000 shares.
Creeping up nicely.
Wouldn't be that surprised if this was blue by the end of the trading day.
Wouldn't be that surprised if this ended the trading day in the blue.
Another RNS..
on 6 December 2022 that, on the same date, Gary Bullard, Chairman, purchased 7,564 Ordinary Shares at a price of £3.99 per share and that Elaine Sullivan, a person closely associated to Gary Bullard, purchased 7,500 Ordinary Shares at a price of £4.05 per Ordinary Share.
Just need another 0.73p on S.P. now after top ups. Could be worse and did expect even bigger dips Today. Hopefully all the bad news is priced in and can slowly start rising back up. Just need REVB to come out of suspension now. Dont I just pick em....
I agree, SP has dipped but buys way outweigh sells, this is a good long term investment, good dividend too speaks volumes:)
No surprises here this had been pre warned by the company, going forward the rewards will build.
Had to have a top up at these prices as no other way out. Dividend kept is good news but S.P. will take a long time to recover.